Table 1.

Patient characteristics

Age	Gender	Diagnosis	NYHA	EF	CI	PCWP	Drugs
63	M	NF					n.d.
44	M	NF					n.d.
69	M	NF					n.d.
23	M	NF					n.d.
19	M	NF					n.d.
n.d.	n.d.	NF					n.d.
48	M	ICM	III–IV		2.5	18	D, G, N, A, C
58	M	ICM	IV		2.2	22	D, G, N, A
41	F	ICM
51	M	ICM
60	M	ICM	III–IV	25	2.7	30	D, G, A, R
61	M	ICM			2.8	11	A, B
52	M	ICM		20	1.7	18	D, G, C
43	M	ICM	III–IV		2.0	11	D, N, A, C
32	F	ICM
47	M	ICM			3.1	16
n.d.	n.d.	ICM	n.d.	n.d.	n.d.	n.d.	n.d.
61	M	DCM	II–III		1.8	21	D, G, N, C, R
53	M	DCM	III	25	2.4	22	D, D, A, C, R
57	M	DCM	III–IV	10–20	2.6	17	D, G, N, A, C
49	M	DCM
51	M	DCM	III–IV	14	2.9	29	D, G, N, A
52	M	DCM	II–III		2.8	11	D, G, A, C, R
43	M	DCM	IV	19			G, A, C
36	M	DCM	III		2.5	26	D, A, C
50	M	DCM	IV				D, C
27	M	DCM			3.4	4

EF (%) LV ejection fraction, CI (l/min m²) cardiac index, PCWP (mmHg) pulmocapillary wedge pressure, D diuretics, G glycosides, N nitrates, A ACE inhibitors or angiotensin II receptor antagonists, C carvedilol, R antiarrhythmics, B β-adrenergic receptor blockers